A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis

Journal of Infectious Diseases

Volumn 190, Issue 5, 2004, Pages 869-878

  Elliott, Alison M ^a,c   Luzze, Henry ^b   Quigley, Maria A ^c   Nakiyingi, Jessica S ^a   Kyaligonza, Steven ^b   Namujju, Proscovia B ^a   Ducar, Constance ^b   Ellner, Jerrold J ^d   Whitworth, James A G ^a,c   Mugerwa, Roy ^b   Johnson, John L ^b   Okwera, Alphonse ^b  

^a UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; ETHAMBUTOL; ISONIAZID; PREDNISOLONE; PYRAZINAMIDE; RIFAMPICIN;

ADULT; AGE; ARTICLE; CELL COUNT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK FACTOR; SEX; SURVIVAL; T LYMPHOCYTE; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOUS PLEURISY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFLAMMATORY AGENTS; ANTITUBERCULAR AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PREDNISOLONE; TREATMENT OUTCOME; TUBERCULOSIS, PLEURAL; VIRAL LOAD;

EID: 4344652895     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/422257     Document Type: Article

References (28)

1. Fred L, Levin MH, Rivo JB, Barrett TE Development of active pulmonary tuberculosis during ACTH and cortisone therapy. JAMA 1951; 147:242-6.
2. Strang JIG, Kakaza HHS, Gibson DG, et al. Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet 1988; 2:759-64.
3. Hakim JG, Ternmouth I, Mushangi E, Siziya S, Robertson V, Malin A. Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart 2000; 84:183-8.
4. Lee C-H, Wang W-J, Lan R-S, Tsai Y-I, Chiang Y-C. Corticosteroids in the treatment of tuberculous pleurisy. Chest 1988; 94:1256-9.
5. Galarza I, Canete C, Granados A, Estopa R, Manresa F. Randomised trial of corticosteroids in the treatment of tubercouls pleurisy. Thorax 1995; 50:1305-7.
6. Wyser C, Walzl G, Smedema JP, Swart F, van Schalkwyk EM, van de Wal BW. Corticosteroids in the treatment of tuberculous pleurisy. Chest 1996; 110:333-8.
7. Ross JD, Horne NW, Crofton J. Modern drug treatment in tuberculosis. 5th ed. London: The Chest Heart and Stroke Association, 1976.
8. Elliott AM, Halwiindi B, Bagshawe A, et al. Use of prednisolone in the treatment of HIV-positive tuberculosis patients. Q J Med 1992; 85:855-60.
9. Vanham G, Edmonds K, Qing L, et al. Generalized immune activation in pulmonary tuberculosis: coactivation with HIV infection. Clin Exp Immunol 1996; 103:30-4.
10. Zhang Y, Nakata K, Weiden M, Rom WN. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat. J Clin Invest 1995; 95:2324-31.
11. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995; 270:283-6.
12. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995; 270:286-90.
13. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication: role of immune activation. J Immunol 1996; 157:1271-8.
14. Whalen CC, Nsubuga P, Okwera A, et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 2000; 14:1219-28.
15. Andrieu J-M, Lu W, Levy R. Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis 1995; 171:523-30.
16. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149:1359-74.
17. McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ. Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed) 1983; 286:923-5.
18. Luzze H, Elliott AM, Joloba ML, et al. Evaluation of suspected tuberculous pleurisy: clinical and diagnostic findings in HIV-1-positive and HIV-negative adults in Uganda. Int J Tuberc Lung Dis 2001; 5:746-53.
19. Sereti I, Lane HC. Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies. Clin Infect Dis 2001; 32:1738-55.
20. Batungwanayo J, Taelman H, Allen S, Bogaerts J, Kagame A, van de Perre P. Pleural effusion, tuberculosis and HIV-1 infection in Kigali, Rwanda. AIDS 1993; 7:73-9.
21. Nagy S, Gyulai R, Kemeny L, Szenohradsky P, Dobozy A. Iatrogenic Kaposi's sarcoma: HHV8 positivity persists but the tumors regress almost completely without immunosuppressive therapy. Transplantation 2000; 69:2230-1.
22. Sato-Matsumura KC, Matsumura T, Nabeshima M, Katano H, Sata T, Koizumi H. Serological and immunohistochemical detection of human herpesvirus 8 in Kaposi's sarcoma after immunosuppressive therapy for bullous pemphigoid. Br J Dermatol 2001; 145:633-7.
23. Sangiorgi G, Orlandi A, De Nardo D, Sangiorgi M, Spagnoli LG. Complete regression of iatrogenic Kaposi's sarcoma due to corticosteroid treatment in a patient with tubercular pericarditis: a case report. Ann Ital Med Int 1993; 8:21-4.
24. Gill PS, Loureiro C, Bernstein-Singer M, Rarick MU, Sattler F, Levine AM. Clinical effects of glucocorticoids on Kaposi's sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989; 110:937-40.
25. Gill J, Bourboulia D, Wilkinson J, et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002; 31:384-90.
26. Ensoli B, Sturzl M, Monini P. Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. Adv Cancer Res 2001; 81:161-200.
27. Elenkov IJ, Chrousos GP. Stress hormones, proinflammatory and anti-inflammatory cytokines, and autoimmunity. Ann N Y Acad Sci 2002; 966:290-303.
28. Dooley DP, Carpenter JL, Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin Infect Dis 1997; 25:872-87.